Ketamine Efficacious for Treatment-Resistant Depression
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, July 21, 2023 -- A four-week treatment course of racemic ketamine is efficacious and safe for treatment-resistant depression (TRD), according to a study published online July 14 in the British Journal of Psychiatry.
Colleen Loo, M.B.B.S., M.D., from the University of New South Wales in Randwick, Australia, and colleagues examined the acute efficacy and safety of a four-week course of subcutaneous racemic ketamine in patients with TRD in a double-blind, randomized, multicenter trial. Participants received twice-weekly subcutaneous racemic ketamine or midazolam for four weeks. Fixed-dose ketamine 0.5 mg/kg versus midazolam 0.025 mg/kg was tested initially (cohort 1; 68 patients); after a Data Safety Monitoring Board recommendation, dosing was revised to flexible-dose ketamine 0.5 to 0.9 mg/kg or midazolam 0.025 to 0.045 mg/kg, with response-guided dosing increments (cohort 2; 106 patients).
The researchers found that ketamine was more efficacious than midazolam in cohort 2 (remission rate, 19.6 versus 2.0 percent; odds ratio, 12.1; 95 percent confidence interval, 2.1 to 69.2; P = 0.005), but not in cohort 1 (remission rate, 6.3 versus 8.8 percent; odds ratio, 1.3; 95 percent confidence interval, 0.2 to 8.2; P = 0.76). Ketamine was tolerated well. Acute adverse effects resolved within two hours.
"Racemic ketamine, given by subcutaneous injection at adequate doses, is safe and efficacious in the therapy of treatment-resistant depression over a four-week treatment course," the authors write. "Benefits attenuate after treatment cessation for most patients, supporting prior evidence that ketamine should be considered as a longer-term treatment."
Several authors disclosed ties to biopharmaceutical companies; one author is named on a patent for a controlled release ketamine tablet developed by Douglas Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Teens May Experience Delays in Bipolar Progression After Major Depressive Disorder
FRIDAY, May 31, 2024 -- Adolescents may experience delayed bipolar disorder (BD) progression after major depressive disorder (MDD) diagnosis, according to a study published online...
Teen Smartphone Use Positively Tied to Mood
THURSDAY, May 30, 2024 -- Adolescent smartphone use is positively associated with mood, according to a study published online May 29 in PLOS ONE. Matt Minich, Ph.D., and...
Changes in Gender Identity Not Tied to Depressive Symptoms in Youth
WEDNESDAY, May 29, 2024 -- Changes in gender identity are not associated with changes in depressive symptoms over time among sexual and gender minority (SGM) youth, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.